Thrombotic microangiopathy in the cancer patient

Hau C. Kwaan*, Leo I Gordon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

63 Scopus citations


Thrombotic microangiopathy, manifesting as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome, is a common complication in cancer patients. It shares the pathogenic microvascular occlusive lesion and many clinical manifestations as the classical TTP, but the spectrum of complications varies widely. Several subsets are seen, including a microangiopathic hemolytic anemia in advanced cancer, chemotherapeutic drug-associated microangiopathy and those with the transplant setting. The prognosis is not as favorable as in classical TTP. Anecdotal reports indicate that responses are seen with plasma exchange and with immunoadsorption.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalActa Haematologica
Issue number1-2
StatePublished - Sep 21 2001


  • Bone marrow transplantation
  • Cancer
  • Chemotherapeutic drugs
  • Hemolytic uremic syndrome
  • Thrombotic microangiopathy
  • Thrombotic thrombocytopenic purpura
  • Von Willebrand factor

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology


Dive into the research topics of 'Thrombotic microangiopathy in the cancer patient'. Together they form a unique fingerprint.

Cite this